| 3.552 -0.028 (-0.78%) | 09-14 13:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.54  |
1-year : | 4.81 |
| Resists | First : | 3.89 |
Second : | 4.11 |
| Pivot price | 3.74 |
|||
| Supports | First : | 3.52 |
Second : | 2.93 |
| MAs | MA(5) : | 3.66 |
MA(20) : | 3.79 |
| MA(100) : | 5.25 |
MA(250) : | 5.75 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 11.7 |
| RSI | RSI(14): 26.5 |
|||
| 52-week | High : | 8.39 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARDX ] has closed below the lower bollinger band by 5.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 69.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.68 - 3.71 | 3.71 - 3.72 |
| Low: | 3.51 - 3.53 | 3.53 - 3.55 |
| Close: | 3.54 - 3.58 | 3.58 - 3.61 |
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Sat, 12 Sep 2026
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Sat, 12 Sep 2026
Ardelyx (ARDX) Could Be 72% Undervalued Following Its September Investor Conference Run - simplywall.st
Sat, 12 Sep 2026
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Fri, 21 Aug 2026
Ardelyx (NASDAQ: ARDX) shareholder John Bishop plans 25,500-share sale - Stock Titan
Fri, 21 Aug 2026
Ardelyx (ARDX) officer to sell 11,900 shares for RSU taxes - Stock Titan
Fri, 07 Aug 2026
Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 258 (M) |
| Shares Float | 211 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 73.4 (%) |
| Shares Short | 22,430 (K) |
| Shares Short P.Month | 26,250 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | -12.4 % |
| Operating Margin | -10.3 % |
| Return on Assets (ttm) | -4.3 % |
| Return on Equity (ttm) | -38.7 % |
| Qtrly Rev. Growth | 23.7 % |
| Gross Profit (p.s.) | 1.31 |
| Sales Per Share | 1.74 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | 20 (M) |
| PE Ratio | -15.46 |
| PEG Ratio | 0 |
| Price to Book value | 5.92 |
| Price to Sales | 2.03 |
| Price to Cash Flow | -53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|